Date: 2015-07-30
Type of information: Licensing agreement
Compound: Captisol-enabled SAR-125844
Company: Ligand Pharmaceuticals (USA - CA) Sanofi (France)
Therapeutic area: Cancer - Oncology
Type agreement: licensing supply
Action mechanism: kinase inhibitor. SAR-125844 is a potent, selective and reversible ATP-competitive MET tyrosine kinase inhibitor for intravenous (IV) administration. SAR-125844 recently completed a first-in-human, open-label, non-randomized, single agent, Phase 1 study in advanced/refractory solid tumor patients. Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Captisol was invented and initially developed by scientists in the laboratories of Dr. Valentino Stella at the University of Kansas’ Higuchi Biosciences Center for specific use in drug development and formulation.
Disease: solid tumors
Details: * On July 30, 2015, Ligand Pharmaceuticals announced it has entered into a global license and supply agreement with Sanofi to utilize Captisol in the development and commercialization of SAR-125844, a potent MET kinase inhibitor. Under the terms of the license, Ligand will be eligible to receive potential milestone payments, royalties on future net sales and revenue from Captisol material sales. Sanofi will be responsible for all costs related to the program.
Financial terms: * On March 4, 2016, in its annual report, Sanofi has announced that the development of SAR125844 in Phase I has been discontinued and Sanofi decided to explore out-licensing opportunities.
Latest news:
